Video

Dr Robert Gabbay Discusses Management of Pediatric Type 1, 2 Diabetes

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.

The American Diabetes Association (ADA) recognizes that type 2 diabetes in young people is a more severe disease, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the ADA.

Transcript

Section 14 of the ADA's 2022 Standards of Medical Care in Diabetes added new information about pediatric type 1 and type 2 diabetes. What is lacking in the care for children?

We recognize that particularly type 2 diabetes in young people is a more severe disease. It progresses more rapidly, and the risk of complications is higher. It's, in essence, a more aggressive disease, and so it's important that clinicians think about how to best manage those individuals and also to screen for them.

Young people with type 1 diabetes continue to be a challenging group and particularly young adults where, if anything, A1C [glycated hemoglobin], not only has it not gotten any better for that population, but it has gotten worse despite all of the technology that's become available. So it was important for us to emphasize the best management about type 1 and type 2 diabetes in children.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo